MedTrace Logo

Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Miscarriages

NCT07796737 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2026-09-01

No results posted yet for this study

Summary

The objective of the trial is to assess whether the combination of enoxaparine (LMWH) with progesterone increases the live birth rate compared to standard of care (no active treatment) in women with unexplained recurrent pregnancy loss.

Conditions

  • Pregnancy Loss
  • Pregnancy Loss, Early

Interventions

DRUG

Vaginal micronized progesterone

Vaginal micronized progesterone 800 mg daily administered in two divided doses .

DRUG

Enoxaparin (LMWH)

Administered subcutaneously once daily at a weight-adjusted prophylactic dose according to body weight or applicable local guidelines.

Sponsors & Collaborators

  • General University Hospital, Prague

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2029-12-31
Completion
2030-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07796737 on ClinicalTrials.gov